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Osteopontin is a proinﬂammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in
multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3  end are a predisposing factor for
MS development and evolution. In this paper, we extended our analysis to a gene variation at the 5  end on the −156G > GG single
nucleotide polymorphism (SNP) and replicated our previous ﬁndings at the 3  end on the +1239A > C SNP. We found that only
+1239A > C SNP displayed a statistically signiﬁcant association with MS development, but both +1239A > Ca n d−156G > GG
hadaninﬂuenceonMSprogression,sincepatientshomozygousforboth+1239Aand −156GGallelesdisplayedslowerprogression
of disability and slower switch to secondary progression than those carrying +1239C and/or −156G and those homozygous for
+1239A only. Moreover, patients homozygous for +1239A also displayed a signiﬁcantly lower relapse rate than those carrying
+1239C, which is in line with the established role of OPN in MS relapses.
1.Introduction
Multiple sclerosis (MS) is an inﬂammatory disease of the
central nervous system characterized by an autoimmune
response against the myelin sheaths and axons, resulting in
progressive neurological dysfunction [1]. Patients with MS
display variable clinical course; at onset, approximately 10%
of patients display a primary progressive form (PP), whereas
theremainderstartoutwitharelapsingremittingform(RR),
and most of them switch to a secondary progressive form
(SP) within 10–30 years [2]. Both genetic and environmental
factors are involved in the development/progression of MS,
and several studies point to a complex inheritance involving
interactionsbetweencombinationsoflocithatmayinﬂuence
the immune response [3, 4]. An increasing bulk of data
suggestthatosteopontin(OPN)mayplayaroleinthepatho-
g e n e s i so fM S[ 5]. OPN is a 60kDa-secreted phosphoprotein
functioning as a free cytokine in body ﬂuids or as an immo-
bilized extracellular matrix molecule in mineralized tissue
[6]. OPN serum levels are increased in several autoimmune
diseases and may inﬂuence development of these diseases
through the OPN immunoregulatory eﬀects enhancing the
proinﬂammatory T helper type 1 (TH1) and TH17 cell res-
ponses and inhibiting the TH2 responses [7].
OPN transcript is abundant in plaques dissected from
brains of patients with MS, whereas it is absent in control2 Clinical and Developmental Immunology
brain tissue; this ﬁnding has been conﬁrmed in rat experi-
mental autoimmune encephalomyelitis (EAE) by microarray
cDNA analysis of spinal cord tissue [8]. OPN serum levels
arehigherinrelapsing-remittingthaninprogressivepatients,
particularly during the relapse [9, 10]. Chowdhury et al.
reported a correlation between cerebrospinal ﬂuid (CSF)
OPN levels and disease activity in patients with MS. These
levels did not correlate with disability status but were higher
in patients with active disease [11].
The human OPN gene (OPN) is located on chromosome
4q22.1, and single nucleotide polymorphisms (SNPs) are
associated with development and/or disease activity of sev-
eral autoimmune diseases [12–14]. A link between the gene
and protein data was suggested by the correlation between
someOPN genotypesandOPNserumlevels[15].FourSNPs
of the OPN gene (+282T > C in exon VI: rs4754; +750C > T
in exon VII: rs11226616; +1083A > G: rs1126772 and
+1239A > C: rs9138) in 3  UTR form three haplotype com-
binations: haplotype A (282T-750C-1083A-1239A), haplo-
type B (282C-750T-1083A-1239C), and haplotype C (282C-
750T-1083G-1239C). Carriers of haplotype B and C dis-
played higher OPN serum levels and higher risk of devel-
oping autoimmune diseases than haplotype A homozygotes.
Several data suggested that the high OPN levels were due to
increased stability of the mRNA coded by haplotype B and
C[ 15]. Regarding MS, we previously found that haplotype
A homozygotes displayed about 1.5 lower risk of developing
MS and lower OPN serum levels than haplotype B or C
carriers. Moreover, clinical analysis showed that haplotype A
homozygous patients displayed slower switching from a RR
to a SP form and milder disease with slower evolution of
disability than patients carrying haplotype B or C [16].
Interindividual diﬀerences of OPN expression may be
also inﬂuenced by variations in the promoter region of
OPN that may modulate its transcriptional activity. This role
has been suggested for the −66T > G[ 17], −156G > GG
(rs7687316), and −443>T > C[ 17]S N P sb yG i a c o p e l l ie ta l .
[18], and we detected a combined eﬀect of −156G > GG and
+1239A > Co nr i s ko fs y s t e m i cl u p u se r y t h e m a t o s u s( S L E )
development [14].
According to these ﬁndings, the aims of this study were
(1) to replicate our previous ﬁndings on the +1239A>CS N P ,
(2) to investigate the role of the −156G > GG SNP, (3), to
assess the impact of these variations on disease evolution.
2. MaterialsandMethods
2.1. Patients. We analyzed 728 Italian patients (278 males,
450 females; M/F: 0.62) with MS diagnosed according to the
revised McDonald criteria [19] and 1218 randomly selected
ethnically and age-matched healthy controls. Patients were
consecutive patients enrolled from the Multiple Sclerosis
C e n t e r so ft h e“ A m e d e oA v o g a d r o , ”U n i v e r s i t yo fE a s t e r n
Piedmont (Novara), the University of Milan, IRCCS Poli-
clinico Hospital (Milan), the Don C Gnocchi Foundation,
I R C C S ,SM a r i aN a s c e n t e( M i l a n ) ,a n dt h e“ S a n t aC r o c e
e Carle” Hospital (Cuneo), Italy. Their clinical and demo-
graphic features were similar to those of other series [20, 21].
Controls were consecutive Italian donors obtained from the
transfusion services of the respective hospitals. Patients and
controls were unrelated, Caucasian and Italian, matched for
age and gender, with no family history of autoimmune
diseases in ﬁrst degree relatives. According to their clinical
course, patients were deﬁned as follows [22]:
RR: occurrenceof exacerbations, eachlasting at least24h
and separated by at least one month of inactivity, with full
recovery or sequelae (n = 447);
PP: steady worsening of symptoms and signs from onset
for at least 6 months, whether superimposed with relapses or
not, with occasional plateau and temporary minor improve-
ments; (n = 71);
SP: initial RR course followed by steady worsening of
symptoms and signs for at least 6 months, whether super-
imposed with relapses or not, with minor remissions, and
plateau (n = 210).
We performed an analysis of the following outcome
measures: time to reach Kurtzke expanded disability status
scale [23] (EDSS) score > 3.0 and time to reach a progressive
course, since it was previously shown that OPN SNPs at the
3  UTR region may inﬂuence these measures in MS patients
[16]. According to Hawkins and McDonnell [24], disease of
patients who, after at least 10 years from onset, had a mild
disability, that is, EDSS score ≤ 3.0, was deﬁned benign MS.
Patients who reached secondary progression within 10 years
from onset were deﬁned fast progressive. Patients who did
not reach the endpoints were excluded.
In RR patients, EDSS score was assessed in remission
phase.
T h ea n n u a lr e l a p s er a t eb e f o r et r e a t m e n tw a sc o l l e c t e di n
327 patients with bout onset (RR patients and SP patients)
[21]. Only relapses that occurred in the ﬁrst three years of
disease were included in the analysis.
Samples from patients with RR were drawn during
remission.Allpatientsgavetheirinformedconsentaccording
totheDeclarationofHelsinki[25].Theresearchwasapprov-
ed by the local ethical committee.
2.2. DNA Analysis. Genomic DNA was isolated from periph-
eral blood mononuclear cells (PBMCs) using standard
methods and primers used to evaluate OPN SNPs were the
following: 5 -gccgtgaattccacagccatg-3  (OPN F) 5 -ttgaa-
tgtaataagaatttggtgg-3  (OPN R)(for +1239 SNP) and 5 -
agccctctcaagcagtcatc-3  (promo 1F) 5 -cctgtgttggtggaggatgt-
3  (promo 1R) (for −156 SNP). PCR products were puriﬁed
withtheEXO/SAPkit(GE,Healthcare,Piscataway,NJ,USA).
SequencingwasperformedwiththeABIPRISMRBigDyeTM
Terminator kit (Applied Biosystems, Foster City, CA) on
an automatic sequencer (Applied Biosystems 3100 Genetic
Analyser) according to the manufacturer’s instructions.
2.3. OPN ELISA Assay. Serum OPN concentrations were
evaluated in a capture enzyme-linked immunoadsorbent
assay (ELISA) according to the protocol provided by the
manufacturer (Calbiochem, San Diego, CA). The optical
density was measured at 450nm with a microplate reader
(Bio-Rad, Hercules, CA). The I-smart program was used toClinical and Developmental Immunology 3
create a regression curve. All assays were performed in
duplicate, and the observer (E.O.) was blinded to the diag-
nosis.
2.4. Statistical Analysis. Allelic frequencies and outcome
measures were compared with the chi-square test with the
Yate’s correction. Relapse rate was compared with the Mann-
Whitney U-test. For the ELISA experiments, the approxi-
mation of population distribution to normality was tested
by using statistics for kurtosis and symmetry. Results were
asymmetrically distributed and consequently presented as
medianvaluesandpercentiles.ELISAdatacomparisonswere
performed with the nonparametric Mann-Whitney U test.
All P values are 2-tailed and the signiﬁcance cut-oﬀ was
P<0.05.
3. Results
We typed the +1239A > C SNP in 728 patients and 1218
controls and the −156G > GG SNP in 728 patients and 912
controls, not overlapping with the cohorts analyzed in our
previous study [16]. The +1239A > CS N Pw a sa n a l y s e d
because it allows to discriminate between the A and non-A
haplotypes (not carrying versus carrying the +1239C allele,
resp.).
Frequency of +1239A homozygotes was decreased in MS
patients compared to controls (46% versus 52%; P = 0.011),
and +1239A homozygotes displayed 1.27 lower risk of MS
than +1239C carriers (Table 1). These ﬁndings conﬁrmed
our previous results on diﬀerent groups of 425 patients and
688 healthy controls, showing that carriers of the +1239A
display a slight protection against MS development. Con-
versely,no statisticallysigniﬁcantdiﬀerence between patients
and controls was found for the −156G>GG SNP (Table 2).
Genotypic distribution did not deviate signiﬁcantly from
the Hardy-Weinberg equilibrium in any group (data not
shown).
The next step was to assess the impact of these varia-
tions on MS evolution, since we previously reported that
+1239A homozygotes displayed slower disease progression
and milder disability over time compared to +1239C carriers
[16]. According to our previous work, disease progression
was evaluated by comparing patients switching from RR to
SP within 10 years from onset (fast progressive, n = 184) and
thoseremainingRRover10years(slowprogressive,n = 444)
and disease severity was evaluated by comparing patients
with an EDSS score ≤ 3.0 ten years or more after onset
(benign MS, n = 194) and those who reached a score > 3.0
within ten years (non-benign MS, n = 446).
Table 3 shows that the proportion of slow progressive
patients was signiﬁcantly higher in +1239A homozygotes
than in +1239C carriers (80% versus 63%, P<0.0001),
whereas no diﬀerence was found between −156GG homozy-
gotes and −156G carriers (73% versus 70%, P = 0.3).
Patients homozygous for both +1239A and −156GG showed
a signiﬁcantly higher proportion of slow progressive patients
than those carrying +1239C and/or −156G (95% versus
Table 1: Frequency distribution of OPN +1239A > Cg e n o t y p e si n
MS patients and healthy controls.
Genotype SNP + 1239 ∗MS (n = 728) †Controls (n = 1218)
AA 335 (46) 634 (52)
AC 314 (43) 486 (40)
CC 79 (11) 98 (8)
AA 335 (46) 634 (52)
Non-AA 393 (54) 584 (48)
‡OR = 1.27 P = 0.011 (95% CI: 1.05–1.54)
∗Multiple sclerosis patients.
†number of subjects and proportions are shown in the brackets. Genotypic
distribution did not deviate signiﬁcantly from the Hardy-Weinberg equilib-
rium in any group (data not shown).
‡Odds ratio (OR), 95% conﬁdence limits (95% CI), χ2 test calculated on
allelic frequencies, and P values are 2-tailed.
Table 2: Frequency distribution of OPN-156G/GG genotypes in
MS patients and healthy controls.
Genotype SNP −156 †MS (n = 728) †Controls (n = 912)
GG/GG 78 (10.7) 112 (12.3)
G/GG 304 (41.8) 384 (42.1)
GG 346 (47.5) 416 (45.6)
‡OR = 0.91 P = 0.25 (95% CI: 0.79–1.06)
∗Multiple sclerosis patients.
†Number of subjects, proportions are shown in the brackets. Genotypic
distribution did not deviate signiﬁcantly from the Hardy-Weinberg equilib-
rium in any group (data not shown).
‡Odds ratio (OR), 95% conﬁdence limits (95% CI), χ2 test calculated on
allelic frequencies, and P values are 2-tailed.
68%, P<0.0001) and those homozygous for +1239A only
(95% versus 80%, P = 0.0094).
Table 3 also shows that the proportion of benign MS
patients was signiﬁcantly higher in +1239A homozygotes
than in +1239C carriers (38% versus 24%, P = 0.0001) and
in −156GG homozygotes than in −156G carriers (46% ver-
sus28%,P = 0.0018).Patientshomozygousforboth+1239A
and −156GG showed a signiﬁcantly higher proportion of
benign MS patients than those carrying +1239C and/or
−156G and those homozygous for +1239A only (52% versus
38%, P = 0.038).
TofurtherevaluatetheclinicalimpactofOPN variations,
we analyzed the relapse rate in bout-onset patients carrying
diﬀerent genotypes. Data were available for 327 patients (157
AA, 170 non-AA). The relapse rate was signiﬁcantly lower
in +1239A homozygotes than in +1239C carriers (0.5/yr
versus 1.3/yr, P = 0.01), whereas no diﬀerence was found
between −156GG homozygotes and −156G carriers (0.8/yr
versus 1.1/yr; P = 0.09) or between subjects carrying both
protective genotypes and those carrying at least one predis-
posing genotype (0.6/yr versus 1.2/yr; P = 0.06) (Table 4).
Finally, we explored whether OPN serum levels varied
in patients displaying diﬀerent outcomes. Consistently, we
found that benign patients, as well as slow progressive
patients, showed signiﬁcantly lower protein levels compared
to nonbenign and fast progressive patients, respectively4 Clinical and Developmental Immunology
Table 3: Frequency distribution of diﬀerent outcomes in MS patients carrying diﬀerent OPN genotypes.
Outcome
Genotypes
+1239A > C −156GG > G +1239A > C
−156G > GG
AA C GG/GG G AA C
GG/GG G
Fast progressiveb 57 (20) 127 (37) 18 (27) 166 (30) 3 (5) 181 (32)
Slow progressivea 228c (80) 216 (63) 58 (73) 386 (70) 57 (95) 387 (68)
P<0.0001d P = 0.311 P<0.0001
Benign MSa 110 (38) 84 (24) 36 (46) 158 (28) 35 (52) 159 (28)
Non benign MSb 183 (62) 263 (76) 42 (54) 404 (72) 32 (48) 414 (72)
P = 0.0001 P = 0.0018 P = 0.0002
aPatients displaying RR form (slow progressive) or EDSS ≤ 3 (benign MS) after 10 years from onset.
bNumber of patients displaying that disease status; proportions are shown in brackets.
Patients displaying either RR course and less than 10 years of followup (29/728) or PP course (71/728) were excluded from the analysis of progression. Patients
displaying EDSS ≤ 3.0 and less than 10 years of followup (88/728) were excluded from the analysis of disability.
cPatients switching to SP form (fast progressive) or reaching EDSS > 3 (non-benign MS) within 10 years from onset.
dStatistical analysis was performed by comparing the diﬀerent outcomes with the χ2 test.
Total number in the analysis of progression: 628 patients: 285 AA; 343 non-AA; 76 GG; 552 non-GG; 60 AAGG; 568 non-AAGG.
Total number in the analysis of course 640 patients: 293 AA, 347 non-AA; 78 GG, 562 non-GG; 67 AAGG, 573 non-AAGG.
Table 4: Relapse rate in patients with bout onset displaying diﬀerent OPN genotypes.
Outcome measure
Genotype
AA
N = 153
C
N = 174
GG/GG
N = 33
Non-GG
N = 294
AAGG
N = 26
CG
N = 301
Relapse rate 0.5a (0.2–1) 1.3 (0.6–1.7) 0.8 (0.4–1.2) 1.1 (0.5–1.3) 0.6 (0.2–1.3) 1.2 (0.5–1.5)
P = 0.01b P = 0.09 P = 0.06
aMedian values; interquartile ranges are shown in the brackets.
bMann-Withney U test.
(median value 132 versus 237ng/mL, interquartile range 94–
164 versus 189–289ng/mL, P<0.0001; median value 154
versus 280ng/mL, interquartile range 100–207 versus 228–
341ng/mL, P =< 0.0001).
4. Discussion
This work stems from our previous observation of a protec-
tive eﬀect of +1239A homozygosity at the 3 UTR of OPN
for MS development and evolution. In our previous paper,
this genotype decreased the risk of MS development by 1.56-
fold [16]. The parallel observation of a combined eﬀect of
+1239C and −156G on risk of (SLE) development [14]
prompted this work extending the OPN analysis in MS to
−156GG > G.
Thecurrentdata,obtainedonamuchlargerindependent
population, replicated our previous ﬁndings on +1239A >
C, showing that the frequency of +1239A homozygotes was
decreased in MS patients and that these subjects displayed
1.27 lower risk of MS development than +1239C carriers.
T h es a m eS N P si nt h e3   UTR region of the OPN gene have
been studied in 326 Spanish MS patients and 484 controls
by other authors. They did not ﬁnd statistically signiﬁcant
diﬀerences between patients and controls, and this apparent
discrepancy might be explained by diﬀerences in both size
and ethnic background of the population under study [26].
By contrast, analysis of −156G > GG SNP did not detect
statistically signiﬁcant diﬀerences between patients and
controls (OR 0.91, P = 0.25), which indicated that this
genetic variation was not associated to MS development. To
our knowledge, this is the ﬁrst paper on this SNP in the MS
population.
The most intriguing results were those on the role of
these SNPs on the MS course. On the one hand, this study
not only conﬁrmed the correlation between +1293A > Ca n d
disease progression, but also strengthened this ﬁnding show-
ing that +1239A homozygotes displayed a lower relapse rate
than the other patients. On the other hand, it detected an
additional eﬀect of −156G > GG on disease progression
since patients homozygous for both +1239A and −156GG
displayedamilderdisease,withslowerprogressionofdisabil-
ity and slower switch to secondary progression, than those
carrying +1239C and/or −156G and those homozygous for
+1239A only. Therefore, −156GG homozigosity in the 5 
end of the gene conferred a further protection especially in
subjects also carrying the protective genotype at the 3  end of
the gene.
These protective eﬀects might be related to functional
outcomes of these OPN variations. In our previous work,
in fact, we showed that +1293C was associated with a highClinical and Developmental Immunology 5
“baseline” production of serum OPN, possibly related to
increased stability of the OPN mRNA [15]. Moreover, posi-
tion −156 seems to fall in a putative binding site for a com-
ponent of the RUNX family of transcription factors and
might inﬂuence osteopontin expression [18].
A further point supporting a protective role of AA
genotype is provided by the analysis of OPN serum levels in
patients displaying diﬀerent disease outcomes. As a matter of
fact, patients showing increased frequency of AA genotype,
that is, benign and slow progressive MS patients, displayed
lower OPN levels. Moreover, our ﬁndings are in line with
the work by Kariuki SN et al. who reported that OPN gene
variants modulate cytokine levels in SLE [27].
In conclusion, this work conﬁrms that osteopontin and
the OPN gene may be involved in MS development and,
especially, progression. These observations suggest that this
cytokine may be a therapeutic target to counteract MS pro-
gression supporting the ﬁnding of Steinman et al. showing
that anti-OPN antibodies ameliorate the disease course in
experimental autoimmune encephalomyelitis [28].
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